https://www.selleckchem.com/pr....oducts/R7935788-Fost
24, p less then 0.001). In all three disease subtypes, patients in CR at allo-HSCT tended to have a lower cumulative incidence of relapse than did those in non-CR (T-ALL 13.6 % vs. 50.0 %, p = 0.10; T-LBL 20.0 % vs. 50.0 %, p = 0.21; B-ALL 10.0 % vs. 56.0 %, p less then 0.01). Thus, the outcomes of allo-HSCT for T-ALL/LBL were comparable to those of Ph-negative B-ALL. Irrespective of the disease subtypes, achieving CR before allo-HSCT was associated with a favorable OS. Further advances in chemotherapy before allo-HSCT and
Like
Comment
Share
